SUDARSHAN
SUDARSHAN PHARMA INDUSTRIES financials
- Market cap
- ₹722 Cr
Quarterly results
Q1 FY27: revenue up 16.4%, net profit up 61.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 124 | 116 | 162 | 142 | 167 +35% | 158 +37% | 200 +24% | 166 +16% |
| EBITDA | 12 | 8 | 15 | 10 | 10 −23% | 11 +35% | 18 +20% | 16 +58% |
| Net profit | 5 | 3 | 7 | 4 | 4 −19% | 4 +56% | 10 +36% | 6 +62% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +21.4% 1Y
1Y: ₹32.12 on 10 Sept 2025 → ₹39. High ₹42.31 (21 Jul 2026), low ₹19.23 (27 Jan 2026).
Financials, as filed
Revenue grew 32.8% a year over 1 year, FY25 to FY26. Operating margin held at 7.3%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹502 Cr | ₹668 Cr |
| Operating profit | ₹38 Cr | ₹49 Cr |
| Operating margin | 7.5% | 7.3% |
| Interest | ₹16 Cr | ₹25 Cr |
| Depreciation | ₹3 Cr | ₹3 Cr |
| Net profit | ₹14 Cr | ₹22 Cr |
| Net margin | 2.8% | 3.3% |
| Cash from operations | ₹35 Cr | ₹-3 Cr |
| Free cash flow | ₹34 Cr | ₹-52 Cr |
| ROCE | 15.0% | 15.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹10 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr |
| Reserves | ₹13 Cr | ₹20 Cr | ₹77 Cr | ₹88 Cr | ₹116 Cr | ₹129 Cr |
| Borrowings | ₹30 Cr | ₹31 Cr | ₹34 Cr | ₹107 Cr | ₹219 Cr | ₹282 Cr |
| Other liabilities | ₹47 Cr | ₹77 Cr | ₹97 Cr | ₹66 Cr | ₹148 Cr | ₹159 Cr |
| Total liabilities | ₹99 Cr | ₹138 Cr | ₹232 Cr | ₹285 Cr | ₹507 Cr | ₹594 Cr |
| Fixed assets | ₹6 Cr | ₹6 Cr | ₹20 Cr | ₹21 Cr | ₹53 Cr | ₹94 Cr |
| Capital work in progress | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹28 Cr | ₹3 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹12 Cr | ₹17 Cr | ₹2 Cr | ₹8 Cr |
| Other assets | ₹93 Cr | ₹130 Cr | ₹200 Cr | ₹245 Cr | ₹424 Cr | ₹489 Cr |
| Total assets | ₹99 Cr | ₹138 Cr | ₹232 Cr | ₹285 Cr | ₹507 Cr | ₹594 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, promoters added +1.54 pp while FIIs trimmed −0.91 pp. The shareholder count shrank 12% to 1,217.
- Promoters
- 58.9%
- FIIs
- 19.9%
- Government
- 0.1%
- Public
- 21.1%
Since Sep 2025
- Promoters +1.54 pp
- FIIs −0.91 pp
- Public −0.61 pp
How it drifted, 11 quarters
Over this window the public fell from 39.0% to 21.1% — −17.9 pp.
Ownership split by quarter, oldest first. Mar '23: Promoters 57.4%, FIIs 3.6%, Public 39.0%.Sep '23: Promoters 57.4%, FIIs 1.4%, Public 41.2%.Mar '24: Promoters 57.4%, FIIs 1.4%, Public 41.2%.Sep '24: Promoters 57.4%, FIIs 13.1%, Public 29.5%.Mar '25: Promoters 57.4%, FIIs 18.4%, Public 24.2%.Jun '25: Promoters 57.4%, FIIs 19.5%, Government 0.1%, Public 23.1%.Sep '25: Promoters 57.4%, FIIs 20.8%, Government 0.1%, Public 21.8%.Dec '25: Promoters 57.4%, FIIs 19.8%, Government 0.1%, Public 22.8%.Mar '26: Promoters 57.4%, FIIs 19.9%, Government 0.1%, Public 22.6%.Jun '26: Promoters 58.9%, FIIs 19.4%, Government 0.1%, Public 21.6%.Aug '26: Promoters 58.9%, FIIs 19.9%, Government 0.1%, Public 21.1%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- North Star Opportunities Fund Vcc-Bull Value Incorporated Vcc Sub-Fund FPI fund newly disclosed 1.65% held
- Saumik Ketankumar Doshi +1.00 pp 2.62% held
The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of SUDARSHAN PHARMA INDUSTRIES LIMITED above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Sachin Vasantrai Mehta | 28.32% | unchanged |
| Hemal Vasantrai Mehta | 27.45% | unchanged |
| Multitude Growth Funds Limited FPI fund | 4.23% | −0.45 pp |
| Century India Opportunity Fund Pc FPI fund | 3.24% | unchanged |
| Saumik Ketankumar Doshi | 2.62% | +1.00 pp |
| Eminence Global Fund Pcc- Eubilia Capital Partners FPI fund | 1.95% | unchanged |
| Ebisu Global Opportunities Fund Limited FPI fund | 1.92% | unchanged |
| Coeus Global Opportunities Fund FPI fund | 1.68% | unchanged |
| North Star Opportunities Fund Vcc-Bull Value Incorporated Vcc Sub-Fund FPI fund | 1.65% | newly disclosed |
| Bridge India Fund FPI fund | 1.59% | unchanged |
| Nexpact Limited FPI fund | 1.50% | −0.33 pp |
| Devangi Hemal Mehta | 0.92% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse SUDARSHAN PHARMA INDUSTRIES LIMITED
Guides on how to read this kind of business and the numbers that matter.